What we now observe is a blistering condemnation of cholesterol-lowering statin drugs coming out of news sources in Great Britain with absolute silence on the subject from US-based news agencies.
The scathing denunciation of statin drugs emanates from The Pharmaceutical Journal in the UK that declares the cholesterol hypothesis of cardiovascular disease is “dead.”
The prevalent mantra that statins are “life-savers” and that “people will die” if they discontinue statins, as well as advice “everyone over 50 should be on a statin drug,” is based upon “cherry-picking” of the data say investigators. A review of 44 published trials of statin drugs finds among subjects taking statins to prevent heart attacks, these pills only add 4 days to one’s life!
Even the newly introduced evolocumab (Repatha), which is an injected drug that reduces circulating cholesterol by a whopping 60% only reduced the incidence of non-fatal heart attacks by 1.5%.
Hoax on humanity
The revelation that Big Pharma and its minions of medical journal editors and medical journalists have pulled off a giant hoax on humanity is an example of the growing realization of a cabal that continues to perpetrate medical falsehoods under the guise of science.
French researchers conclude it is possible “nobody benefits from statins.”
The Cochrane global network of researchers who analyze the risks and benefits of medicines calls for a “do not resuscitate” order on cholesterol as the cause of heart disease.” This means, bury the cholesterol paradigm now and forever. But again, this clarion call is coming from British-based news press.
Don’t expect a U turn anytime soon
Certainly such a ruse represents a whopper of a lie. About a quarter of Americans over 45 years of age take statins as pharmaceutical companies rake in billions of dollars in sales.
Will any of the recent revelations about statin drugs change the course of modern medicine? Will guidelines for medical care of patients who have experienced heart attacks and those who are at higher risk (primary prevention) be scrapped?
Investigators write in The Pharmaceutical Journal: “When looking at the totality of the evidence, the sobering results of these studies have left many doctors wondering whether the directive to lower LDL-C aggressively using pharmacotherapy has been misguided. ‘Big Pharma’ has certainly triumphed, yet the patients have not… Furthermore, contrary to reports about stopping statins as a consequence of media scare stories about side effects resulting in thousands of heart attacks and deaths, there is no scientific evidence from registry data of a single person suffering such a fate.”
These investigators suggest the abandonment of cholesterol as the prevailing paradigm in modern medicine and replacement with “insulin resistance” as the true culprit behind cardiovascular disease, diabetes and obesity.
They claim correction of insulin resistance could prevent 42% of heart attacks. They put the blame on dietary practices, namely intake of refined sugars and refined carbohydrates (bread, pasta, cereals and rice). They lambast public health authorities for misdirected dietary guidelines.
The one Health journalist who dared to reveal all about statin drugs, Dr. Maryanne Demasi, was attacked for questioning the statin/cholesterol propaganda. Obviously, other intimidated journalists decided to fall in line and not speak out.
Statin drug profits
Statins as a class represent the world’s most successful selling drug. The first 14.5 years of marketing Lipitor, the world’s leading statin drug, generated $125 billion in sales. Lipitor was introduced in 1997.
Did the weight of the scientific evidence carry statin drugs to the top of the list in drug sales? Or was it influence peddling by the drug industry that buoyed statin drugs on Wall Street?
The prescription drug industry is reported to have spent $5.2 billion on advertising drugs directly to consumers in 2015.
While conflict of interest disclosures are required for authors of published studies, the news media, which is the recipient of billions of dollars of advertising dollars from Big Pharma, has obvious conflicts of interest that go undisclosed, especially by ignoring the present breaking news emanating out of Great Britain over the ineffectiveness of statin drug.
The evening news on television in the US is virtually owned by pharmaceutical companies.
Should direct-to-consumer drug ads be banned?
National Public Radio characterized direct-to-consumer drug advertising as “selling sickness.”
A recent article in the Los Angeles Times says direct-to-consumer drug advertising is a “bad idea that is about to get worse.” The article says burgeoning health care costs coincided with the green light given by the FDA in 1997 for these ads.
There has been talk in Congress for a couple of years now of eliminating financial incentives doctors have for prescribing the most expensive drugs, but nothing substantial has been done. Congress is likely to grandstand hearings but stop short of outlawing direct-to-consumer advertising altogether.
With Big Pharma spending $2.6 billion on lobbying Congressional representatives between 1998 thru 2012, bribery is alive and well in Washington DC. Do Congressmen recuse themselves from voting on pharmaceutical drugs or even disclose during hearings of their acceptance of donations from the pharmaceutical lobby? Hell no! Congressmen ought to wear hats emblazoned with the names of their sponsors like winners of auto races do.
Big Pharma has also enlisted big-time professors at major medical institutions to endorse their products. For example, experts at top universities have been active in promoting new $1000/day cures for hepatitis C.
Recently it was revealed how drug companies gouge insurance pools. For example, a compound drug for gastroesophageal reflux that sells for $9027 was found be comprised of individual elements that cost $20. The two components for a $1471 anti-migraine drug were found to cost only $37 when purchased individually.
It’s even been suggested that the US government buy out a drug company to save money.
Will investment advisors begin to advise their clients to bet against Big Pharma’s stocks as Congress considers restrictions on the industry? Just wait till Big Pharma enters the marijuana market. Imagine the direct-to-consumer ads?